Abstract:The malignant transformation of normal cells is driven by both genetic and epigenetic changes. With the advent of next-generation sequencing and large-scale international consortia, it is now possible to profile the genomes and epigenomes of thousands of primary tumors from nearly every cancer type. These studies clearly demonstrate that the dynamic regulation of DNA methylation is a critical epigenetic mechanism of cancer initiation, maintenance, and progression. Proper control of DNA methylation is not only crucial for regulating gene transcription and tissue-specific cellular functions, but its broader consequences include maintaining the integrity of the genome and modulating the immune response. Here, we describe the aberrant DNA methylation changes in human cancers and how they contribute to the disease phenotypes. Aside from CpG island promoter DNA hypermethylation-based gene silencing, human cancers also display gene body DNA hypomethylation that is also associated with downregulated gene expression. In addition, the implementation of whole genome bisulfite sequencing (WGBS) has unveiled DNA hypomethylation of large blocks of the genome, known as partially methylated domains (PMDs), as well as cancer-specific DNA methylation aberrancies at enhancers and super-enhancers. Integrating WGBS and DNA methylation array data with mutation, copy number, and gene expression data has allowed for the identification of novel tumor suppressor genes and candidate driver genes of the disease state. Finally, we highlight potential clinical implications of these changes in the context of prognostic and diagnostic biomarkers, as well as therapeutic targets. Mounting evidence shows that DNA methylation data are effective and highly-sensitive disease classifiers, not only from analyses of the primary tumor but also from tumor-derived, cell free DNA (cfDNA) in blood of cancer patients. These findings highlight the power of DNA methylation aberrancies in providing efficacious biomarkers for clinical utility in improving patient diagnostics and their reversal using DNA methylation inhibitors in cancer treatment may be key in surveillance, treatment, and quality of life for cancer patients.

Technologies for Targeting DNA Methylation Modifications: Basic Mechanism and Potential Application in Cancer.

Deoxyribonucleic Acid 5-Hydroxymethylation in Cell-Free Deoxyribonucleic Acid, a Novel Cancer Biomarker in the Era of Precision Medicine

DNA Methylation: From Cancer Biology to Clinical Perspectives

Advances in Targeted Induction of DNA Methylation and Cancer Therapy

DNA Hypermethylation As a Chemotherapy Target.

Methylomics and cancer: the current state of methylation profiling and marker development for clinical care

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

DNA Methylation Profiles in Cancer Diagnosis and Therapeutics

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Epigenetic Regulation in Cancer Therapy: from Mechanisms to Clinical Advances

Translational Application of DNA Methylation Biomarkers in Malignant Tumors

Emerging role of different DNA methyltransferases in the pathogenesis of cancer

The Role of DNA Methylation and DNA Methyltransferases in Cancer

The potential of DNA modifications as biomarkers and therapeutic targets in oncology

Methylation modification of non-histone proteins in breast cancer: an emerging targeted therapeutic strategy

Targeting DNA methyltransferases for cancer therapy

DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective

A Profile of Current Methods for Dna Methylation Analysis

Research Progress on DNA Demethylation in Anti-Tumor Therapy

Relationship Between DNA Methylation/demethylation and Cancer